In 1985, Novo Nordisk pioneered production of recombinant human insulin in yeast. In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering ...

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. The growth of the global rapid acting ...

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin ... as a biosimilar under the name Insulin lispro Sanofi ...

Slight structural modifications in Lispro result in less self-association and more rapid therapeutic onset. The '477 patent issued to Aradigm covers the use of monomeric insulin as a means for ...

Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said on Wednesday. The ...